• Accelerated integration of Sanity Group into Organigram’s global corporate structure marks next phase of international growth strategy
• Sanity founder Finn Hänsel appointed Chief Strategy Officer & President, Rest of World, Adrian Frenzel takes charge of Organigram’s operations as Global Chief Operating Officer; Tim Emberg to remain President, Canada
• Organigram’s integrated supply and commercial network will now span Canada, Germany, Switzerland, Poland, Czechia, the United Kingdom and Australia
• Sanity Group contributed approximately CAD$40 million, or 35 percent, to Organigram’s consolidated net revenue in the most recent quarter and was accretive to Adjusted EBITDA
• Strong growth momentum: Driven by the combination, quarterly revenue rose 34 percent over the last two calendar quarters to €25.5 million 

Sanity Group GmbH (“Sanity Group”), one of Europe’s leading medical cannabis companies, today announced the successful completion of its strategic transaction with one of Canada’s leading licensed cannabis producers Organigram Global Inc (“Organigram”). With the closing, both companies enter the next phase of a their shared mission to build a globally leading pure-play cannabis company. Together, they intend to accelerate their international growth strategy and shape the development of the European cannabis market. “The completion of this transaction marks an important next step,” said Finn Hänsel, founder and CEO of Sanity Group. “With expanded capabilities in research and development as well as additional production capacity, we are now in a position to significantly accelerate and scale our activities in Germany and across Europe.”

Berlin, April 1, 2026 – On the second anniversary of the German Cannabis Act (CanG) coming into effect, the second interim report on the Evaluation of the Recreational Cannabis Act (EKOCAN) was published today. From Sanity Group’s perspective, this marks another important milestone toward an evidence-based cannabis policy in Germany: The data now available will help to assess the effects of this new regulation in a nuanced manner and to further develop the existing legal framework on a scientific basis. “The Cannabis Act was an important and long-overdue paradigm shift,” explains Finn Hänsel, founder and CEO of Sanity Group. “Two years later, it is clearer how important it is to develop regulations not ideologically but based on data.”

Sanity Group, one of Germany’s leading cannabis companies, is delighted to announce a partnership with Curaleaf Laboratories, one of the UK-leading pharmaceutical-grade medical cannabis manufacturers. The partnership brings together Sanity Group’s international expertise in cannabinoid-based therapeutics with Curaleaf Laboratories’ established manufacturing, quality, and commercial capabilities. Together, the companies will collaborate to develop, manufacture, and commercialize innovative medical cannabis products tailored to the needs of UK patients and healthcare professionals.